Community-acquired pneumonia is a common infection and a leading cause of morbidity and mortality worldwide.
Community-acquired pneumonia (CAP) is a common infection and a leading cause of morbidity and mortality worldwide.1
CAP is caused mostly by viruses and bacteria, with Streptococcus pneumoniae being the most common, followed by others such as Haemophilus influenzae and atypical bacteria.2 Several antibiotic stewardship opportunities are available for pharmacists in the management of CAP.
Infectious Diseases Society of America (IDSA) guidelines for CAP recommend either doxycycline or a macrolide for outpatients without risk factors for drug-resistant S pneumoniae (DRSP).3
For outpatients with local macrolide resistance >25% or risk factors for DRSP (presence of comorbidities, diabetes mellitus, alcoholism, malignancies, asplenia, immunosuppressing conditions, use of immunosuppressing drugs, use of antimicrobials within the previous 3 months, and/or old age) and inpatients not admitted to the intensive care unit (ICU), a respiratory fluoroquinolone (levofloxacin and moxifloxacin) or a combination of a β-lactam (aminopenicillin or second- or third-generation cephalosporins) and either doxycycline or a macrolide is recommended. Patients with corrected QT (QTc) prolongation should receive doxycycline because it is the primary option for atypical bacteria that do not prolong QTc, and it seems to be neutral in terms of increasing risk to Clostridium difficile infection, unlike fluoroquinolones and macrolides.4 For ICU inpatients, a β-lactam with either azithromycin or levofloxacin is recommended. Antibiotics active against methicillin-resistant Staphylococcus aureus (MRSA) and Pseudomonas aeruginosa are not needed in most patients. Therefore, an assessment of risk factors is needed to reduce inappropriate use and microbial resistance. However, if MRSA is present, linezolid or vancomycin can be added, while patients with risk factors for P aeruginosa should be treated with an antipseudomonal/antipneumococcal β-lactams (cefepime, imipenem, meropenem, or piperacillin-tazobactam) with one of the following regimens: aminoglycoside and azithromycin, aminoglycoside and levofloxacin, or ciprofloxacin or levofloxacin. In general, fluoroquinolones should be avoided because of several recent warnings of adverse events.3
CAP is one of the primary infections for which implementing a facility-specific clinical practice protocol for its management is strongly recommended.5 Prospective audits with intervention and feedback to prescribers can enhance adherence to guidelines and reduce overall antibiotic use, length of hospital stay (LOS), and duration of therapy (DOT) without compromising clinical outcomes.6-11 Switching from intravenous to oral antibiotics in clinically stable patients is an important target for improving clinical outcomes and cost. A meta-analysis of randomized controlled trials (RCTs) of patients with CAP who switched early to oral antibiotics showed no difference in clinical outcomes but reduced LOS and adverse drug events.12 In terms of CAP prevention, pharmacists can contribute mainly by promoting influenza and pneumococcal vaccinations.
Because CAP requires empiric antimicrobial therapy, adherence to guidelines and de-escalation are major antibiotic stewardship opportunities. Several observational studies found no association of de-escalation with increased mortality, clinical failure, or increased LOS.13-16 Other studies observed that concordance with recommended antimicrobial therapy by guidelines is associated with lower mortality and lower LOS and DOT.17-19 Unfortunately, unnecessary continuation of antimicrobial therapy for CAP is a common practice.2 Shortening DOT is another key intervention that can reduce adverse reactions, antimicrobial resistance, cost, and LOS.20,21 The IDSA guidelines recommend a minimum duration of antibiotic therapy of 5 days if the patient is afebrile for 48 to 72 hours and has no more than 1 CAP-associated sign of clinical instability.3 Several RCTs and meta-analyses of RCTs did not demonstrate any difference in clinical outcomes in patients treated with long versus short antibiotic courses.22-24 Procalcitonin can assist pharmacists in deciding on earlier discontinuation of antibiotic therapy.5 Nasal screening of MRSA can be a useful tool to avoid unnecessary empiric therapy for MRSA in patients with CAP who are not colonized with MRSA.25 Urine antigen tests can be used to de-escalate to targeted antibiotics for S pneumoniae and Legionella pneumophila serogroup A.3 Anti-influenza agents should be removed as soon the patient with CAP has a negative influenza test.
Optimization of antibiotic dosing and the prevention of drug—drug interactions are additional opportunities for pharmacists. For example, high doses of amoxicillin and co-amoxiclav (1 g q8g and 2 g every 12 hours, respectively) should be used, as they can overcome some penicillin-resistant S pneumoniae strains.3 Chelation of fluoroquinolones and doxycycline with divalent and trivalent cations can occur if coadministered around the same time. Therefore, pharmacists should counsel patients and health care providers to separate time of administration, particularly when several preparations of these cations are OTC.
Khalid Eljaaly, PharmD, MS, BCPS, is an assistant professor and infectious disease pharmacist at King Abdulaziz University in Saudi Arabia and an honorary research fellow at the College of Pharmacy at the University of Arizona Health Sciences in Tucson. He is a member of the social media committees of both the Infectious Diseases Practice and Research Network of the American College of Clinical Pharmacy and the Society of Infectious Diseases Pharmacists (SIDP). In addition, he is a member of the editorial advisory board of Contagion®, a member of the Saudi Arabia Ministry of Health antibiotic stewardship project (ASP) implementation team, and a member of the ASP committee of SIDP.